Anaesthetic effects of propofol polymeric micelle: A novel water soluble propofol formulation

British Journal of Anaesthesia

Volumn 101, Issue 2, 2008, Pages 186-193

  Ravenelle, F ^a   Vachon, P ^b   Rigby Jones, A E ^c   Sneyd, J R ^c   Le Garrec, D ^a   Gori, S ^a   Lessard, D ^a   Smith, D C ^a  

^a Labopharm Inc   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

Anaesthetics i.v, propofol; Copolymer; Formulations, polymeric micelles; Pharmacodynamics; Pharmacokinetics, propofol

Indexed keywords

COPOLYMER; POLY(N VINYL 2 PYRROLIDONE) BLOCK POLY(LACTIDE) COPOLYMER; PROPOFOL; PROPOFOL PM; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CHEMICAL STRUCTURE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SOLUBILITY; MALE; MICELLE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; TWO COMPARTMENT MAMILLARY POPULATION MODEL;

EID: 47249111228     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aen147     Document Type: Article

References (26)

1. Scott RP, Saunders DA, Norman J. Propofol: clinical strategies for preventing the pain of injection. Anaesthesia 1988; 43: 492-4
2. Thomas DV. Propofol supports bacterial growth. Br J Anaesth 1991; 66: 274
3. Hart B. 'Diprivan': a change of formulation. Eur J Anaesthesiol 2006; 17: 71-3
4. Shao X, Li H, White PF, Klein KW, Kulstad C, Owens A. Bisulfite-containing propofol: is it a cost-effective alternative to Diprivan for induction of anesthesia? Anesth Analg 2000; 91: 871-5
5. Parke TJ, Stevens JE, Rice AS, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. Br Med J 1992; 305: 613-6
6. Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology 2005; 103: 860-76
7. Bielen SJ, Lysko GS, Gough WB. The effect of a cyclodextrin vehicle on the cardiovascular profile of propofol in rats. Anesth Analg 1996; 82: 920-4
8. Ravenelle F, Gori S, Le Garrec D, et al. Novel lipid and preservative-free propofol formulation: properties and pharmacodynamics. Pharm Res 2008; 25: 313-19
9. Luo L, Ranger M, Lessard DG, et al. Novel amphiphilic diblock copolymer of low molecular weight poly(N-vinylpyrrolidone)-block-poly(D,L- lactide): synthesis, characterization and micellization. Macromolecules 2004; 37: 4008-13
10. Vachon P, Moreau JP. Serum corticosterone and blood glucose in rats after two jugular vein blood sampling methods: comparison of the stress response. Contemp Top Lab Anim Sci 2001; 40: 22-4
11. Beaudry F, Guenette SA, Winterborn A, Marier JF, Vachon P. Development of a rapid and sensitive LC-ESI/MS/MS assay for the quantification of propofol using a simple off-line dansyl chloride derivatization reaction to enhance signal intensity. J Pharm Biomed Anal 2005; 39: 411-7
12. Wright PMC. Population based pharmacokinetic analysis: why do we need it; what is it; and what has it told us about anaesthetics? Br J Anaesth 1998; 80: 488-501
13. Beal SL, Sheiner LB. NONMEM User's Guide. San Francisco: University of California, 1999
14. Zahn PK, Umali E, Brennan TJ. Intrathecal non-NMDA excitatory amino acid receptor antagonists inhibit pain behaviors in a rat model of postoperative pain. Pain 1998; 74: 213-23
15. Varvel JR, Donoho DL, Shafer SL. Measuring the predictive performance of computer-controlled infusion pumps. J Pharmacokinet Biopharm 1992; 20: 63-94
16. 2 anesthesia used for restraint during serial blood collection via the jugular vein. J Am Assoc Lab Anim Sci 2006; 45: 17-22
17. Yeganeh MH, Ramzan I. Determination of propofol in rat whole blood and plasma by high-performance liquid chromatography. J Chromatogr 1997; 691: 478-82
18. Dutta S, Matsumoto A, Muramatsu M, Matsumoto M, Fukuoka M, Ebling WF. Steady-state propofol brain:plasma and brain:blood partition coefficients and the effect-site equilibration paradox. Br J Anaesth 1998; 81: 422-4
19. Shyr MH, Tsai TH, Tan PP, Chen CF, Chan SH. Concentration and regional distribution of propofol in brain and spinal cord during propofol anesthesia in the rat. Neurosci Lett 1995; 184: 212-5
20. Coetzee JF, Glen JB, Wium CA, Boshoff L. Pharmacokinetic model selection for target controlled infusions of propofol. Assessment of three parameter sets. Anesthesiology 1995; 82: 1328-45
21. Fan SZ, Yu HY, Chen YL, Liu CC. Propofol concentration monitoring in plasma or whole blood by gas chromatography and high-performance liquid chromatography. Anesth Analg 1995; 81: 175-8
22. Viernstein H, Stumpf C, Spiegl P, Reiter S. Preparation and central action of propofol/hydroxypropyl-beta-cyclodextrin complexes in rabbits. Arzneimittelforschung 1993; 43: 818-21
23. Egan TD, Kern SE, Johnson KB, Pace NL. The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model. Anesth Analg 2003; 97: 72-9
24. Dutta S, Ebling WF. Formulation-dependent brain and lung distribution kinetics of propofol in rats. Anesthesiology 1998; 89: 678-85
25. Glen JB, Hunter SC. Pharmacology of an emulsion formulation of ICI 35 868. Br J Anaesth 1984; 56: 617-26
26. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003; 42: 665-85